New combination treatments for people with multiple myeloma
Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic Interventions
Researchers are trying combinations of targeted radioactive antibodies, CS1-directed CAR T cells, and an oncolytic virus plus a proteasome inhibitor to create longer remissions for people with multiple myeloma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11168805 on NIH RePORTER |
What this research studies
This project focuses on multiple myeloma and tests combining targeted radioimmunotherapy (using isotopes like 177Lu or 225Ac) with CS1-directed CAR T cell therapy to kill cancer cells more effectively while aiming to use lower doses. It also explores using the oncolytic virus Reolysin together with the drug carfilzomib, since lab work showed the two can kill myeloma cells better together. The goal is to reduce side effects, boost the immune response against the tumor, and produce more durable remissions. Work includes laboratory studies and plans that could translate into patient treatments at City of Hope.
Who could benefit from this research
Good fit: Ideal candidates would be adults with multiple myeloma, especially those with relapsed or refractory disease who may be eligible for advanced therapies like CAR T or clinical trials.
Not a fit: People without multiple myeloma, those with milder or smoldering disease not needing aggressive therapy, or patients ineligible for immunotherapy or investigational treatments may not benefit from this work.
Why it matters
Potential benefit: If successful, these combinations could lead to longer-lasting remissions with fewer side effects for people with multiple myeloma.
How similar studies have performed: CAR T cell therapies have produced remissions in multiple myeloma but relapses remain common, and single-agent oncolytic virus trials showed only modest activity, so the specific combination approach is relatively novel.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Caserta, Enrico — Beckman Research Institute/city of Hope
- Study coordinator: Caserta, Enrico
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.